August 5, 2026 · Annals of surgical oncology · DOI: 10.1245/s10434-026-20341-9

Risk-Adapted Use of Adjuvant Systemic Therapy After Nephrectomy for Renal Cell Carcinoma: A Population-Based Study in the Post-approval Era

Listen to this summary

The authors aimed to characterize the real-world use of adjuvant systemic therapy (AST) in eligible renal cell carcinoma (RCC) patients following nephrectomy and to determine if treatment allocation aligns with established high-risk tumor characteristics. Their analysis of the SEER database revealed that while AST use increased from 13% in 2018 to 36% in 2022, only 18% of eligible patients received AST, with higher usage associated with adverse tumor features such as T4 stage, tumor grade 4, and N1-2 stage. Despite the increase in AST administration, it remained underutilized, particularly among high-risk patients.

Maximilian Filzmayer, Michele Petix, Leonardo Quarta, Filippo Orlandi, Jordan A Goyal, Luca Carmignani, Alberto Briganti, Salvatore Micali, Shahrokh F Shariat, Mike Wenzel, Yasmine Heß-Busch, Clara Humke, Fred Saad, Felix K-H Chun, Pierre I Karakiewicz

This is one of 33,000+ journals available on OSLR. Try it free for 14 days.

Free 14-day trial. 33,000+ journals. Cancel anytime.

14-day free trial. No commitment.

"Oslr has become part of my weekly routine on my day off. The clinical relevance of the summaries is outstanding — I'd rate it 9/10. Being able to consume research hands-free is a huge advantage for busy physicians."

Dr. Jennifer Thompson

Dr. Jennifer Thompson

Portland, OR

Stay current without falling behind

33,000+ journals. 3-minute audio summaries. Free for 14 days.

Download on the App StoreGet it on Google Play